Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment

Basit Öğe Kaydı
dc.contributor.authorTotan, Yuksel
dc.contributor.authorGuler, Emre
dc.contributor.authorGuragac, Fatma Betul
dc.date.accessioned2025-10-24T18:09:44Z
dc.date.available2025-10-24T18:09:44Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractPurpose: To evaluate the safety and efficacy of intravitreal dexamethasone implant (Ozurdex) in patients with chronic diabetic macular edema (DME) resistant to prior intravitreal bevacizumab (IVB) treatment. Materials and Methods: Thirty eyes of 30 patients were administered intravitreal Ozurdex and examined at baseline and 1, 3, and 6 months postinjection in this prospective study. Main outcomes were the best corrected visual acuity (BCVA, logMAR), central foveal thickness (CFT), mean cube volume (MCV), and intraocular pressure (IOP). Patients had a CFT over 275 mu m (measured by OCT) and were unresponsive to 3 consecutive IVB injections. All data are presented as meanstandard deviation. Results: The mean BCVA significantly increased from 0.56 +/- 0.38 to 0.41 +/- 0.27 (p<0.001), and 0.44 +/- 0.28 (p=0.008) at 1 and 3 months, respectively. At months 1, 3, and 6, the mean CFT significantly decreased from 517 +/- 136 mu m at baseline, to 290 +/- 60 mu m (p<0.001), 314 +/- 88 mu m (p<0.001) and 411 +/- 126 mu m (p=0.01), respectively. However, the mean CFT (p<0.001) and MCV (p=0.01) significantly increased and BCVA significantly decreased (p=0.04) at 6 month compared to 3 month. Compared to baseline, IOP increased significantly at 1 week (p=0.01), 1 month (p=0.01) and 3 months (p=0.04). However eyes with IOP higher than 21mmHg were treated and well controlled with topical anti-glaucoma monotherapy. Macular edema recurrence occurred in 25 eyes (CFT ranged from 321 mu m to 800 mu m) at 6 months. Conclusion: Dexamethasone intravitreal implant may be an effective and safe alternative in treatment of chronic DME nonresponsive to regular IVB. However, its therapeutic efficacy decreases between the third and sixth months following the injection.
dc.identifier.doi10.3109/02713683.2014.1002048
dc.identifier.endpage113
dc.identifier.issn0271-3683
dc.identifier.issn1460-2202
dc.identifier.issue1
dc.identifier.pmid25610946
dc.identifier.scopus2-s2.0-84953363003
dc.identifier.scopusqualityQ1
dc.identifier.startpage107
dc.identifier.urihttps://doi.org/10.3109/02713683.2014.1002048
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3780
dc.identifier.volume41
dc.identifier.wosWOS:000367530500014
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofCurrent Eye Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectAnti-VEGF therapy; bevacizumab; corticosteroids; diabetic macular edema; dexamethasone implant; inflammation; Ozurdex
dc.titleDexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment
dc.title.alternativeDexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu